Novartis AG (NVS)

Novartis is a pharmaceutical company of the traditional type: it discovers, develops, manufactures, and sells prescription drugs. Like most large pharmaceutical firms, it is highly diversified across therapeutic areas — the diseases it targets range from cancer to immunological conditions to heart disease to genetic disorders. It also manufactures generics and biosimilars (biological medicines that are chemically equivalent to branded drugs whose patents have expired) through a subsidiary called Sandoz. The company is headquartered in Switzerland and employs roughly 130,000 people across manufacturing, research, and sales operations worldwide.

The pharmaceutical business is fundamentally about the life cycle of patents. A company discovers or acquires a promising molecular compound, invests a decade and billions of dollars testing it in humans, wins regulatory approval, and then has a window of protection — typically 15–20 years from patent filing to expiration — during which the drug is the only legal version available. In that window, the company charges premium prices to recoup its R&D investment and fund new discoveries. When the patent expires, generic manufacturers can make the same molecule for a fraction of the price, and the brand drug’s sales collapse. A pharmaceutical company’s stock price and profitability therefore depends entirely on having a pipeline of newly approved drugs coming to market faster than existing ones are losing patent protection.

Oncology and cellular therapy

Novartis has made oncology — the treatment of cancer — its strategic priority for the past decade. Cancer drugs are among the most profitable in the world because they often extend life or offer remission from a fatal disease, justifying enormous prices. The company has built its oncology franchise through acquisition and internal discovery, accumulating drugs that target different types of cancer using different mechanisms.

The company’s oncology portfolio includes Kisqali (breast cancer), Tafinlar and Mekinist (melanoma and other cancers), Zometa (a support drug used alongside other cancer treatments), and others. These are not perfect cures — none are — but they extend life, improve quality of life, or reduce recurrence risk, and they command prices in the range of $50,000–$200,000 per patient per year. From the company’s perspective, oncology is where the margin is. From the patient and healthcare system perspective, these are extraordinarily expensive treatments that strain budgets and raise questions about access and fairness.

Novartis has also invested heavily in cellular and gene therapy — technologies that are among the most exotic in pharma. Cell therapy involves isolating a patient’s immune cells, genetically engineering them to recognise and attack cancer, and reinfusing the modified cells. Gene therapy involves delivering a functional copy of a gene into a patient’s cells to correct a genetic defect. Both are conceptually powerful and can be curative for certain diseases, but they are extraordinarily expensive to develop and to administer.

The company’s flagship product in this area is Kymriah, a CAR-T cell therapy for certain blood cancers and leukaemias. The treatment can cure some patients, but it costs around $475,000 per patient and carries risks of severe side effects. Novartis sees cellular and gene therapy as the future of medicine, but they remain niche for now — the volume is small, the manufacturing is bespoke (each dose is engineered for an individual patient), and the costs are astronomical.

Immunology and other areas

Beyond oncology, Novartis has significant franchises in immunology — the treatment of autoimmune and inflammatory diseases like rheumatoid arthritis, lupus, and psoriasis. These conditions affect millions of people, require lifelong treatment, and command consistent revenue. A drug for rheumatoid arthritis might cost $20,000–$50,000 per patient per year, in line with chronic disease drugs generally. The patient population is large, the diseases are well-understood, and competition is established, so margins are solid but not as stratospheric as oncology.

The company also has cardiovascular drugs (for heart disease and high blood pressure) and ophthalmology (treating eye diseases like age-related macular degeneration). These are slower-growth areas, but they are stable sources of cash.

Within its portfolio, Novartis’s revenue is concentrated: a relatively small number of drugs generate the majority of sales. This means the company’s fortunes are tied to whether those drugs maintain their market share and pricing power as patents approach expiration or as newer competitors arrive.

Generics and biosimilars: the Sandoz division

Novartis owns Sandoz, one of the world’s largest makers of generic drugs and biosimilars. Generics are chemical copies of branded drugs whose patents have expired; biosimilars are biological copies of patent-expired biologic drugs. Both are much cheaper than the branded versions and form the backbone of healthcare systems’ drug budgets.

The generic and biosimilar business is high-volume, low-margin. A generic drug might sell for 10 percent of the branded price, and the manufacturer makes maybe 20–30 percent gross margin — so very little money per dose, but the volume is enormous. Sandoz is a source of steady cash but not exciting profits.

Strategically, Sandoz creates an interesting tension within Novartis. The branded business wants to sell expensive drugs at high prices to sick patients; the generic business wants to sell cheap drugs at volume. These are not compatible missions, and Novartis has handled the tension by essentially operating them as separate entities. However, there has been recent strategic reconsideration: Novartis has been in discussions about potentially spinning off or separating Sandoz to allow the company to focus its messaging and identity purely on the innovative branded business. The strategic logic is that owning a generics company undermines the premium positioning of the branded pharmaceutical business.

Research, development, and the cost of innovation

Pharmaceutical R&D is brutally expensive. Bringing a single drug to market costs on the order of $2–3 billion in out-of-pocket expense and takes 10–15 years, including all the failures along the way. Novartis spends roughly 15–20 percent of revenue on R&D every year — tens of billions of dollars — on the bet that it will discover new drugs faster than existing ones lose patents.

The innovation process is also slow and stochastic — unpredictable. A company might fund 5,000 potential drug compounds in early research; a few hundred will be promising enough to move into human testing; perhaps one or two will ultimately win approval. Most fail, usually partway through the multi-stage human trials, when it becomes clear the drug does not work or causes unacceptable side effects. From an investor’s perspective, this is maddening — the company invests enormous sums, most of it never produces a return, and success depends partly on luck and scientific discovery that no amount of money can guarantee.

To mitigate this risk, Novartis and its peers acquire promising drugs and companies at various stages of development, hedging their bets across a larger number of shots on goal. Novartis has also invested in technologies like artificial intelligence and machine learning to try to make the drug-discovery process more efficient. Whether these actually accelerate discovery or just change what kinds of failures Novartis experiences is unclear — the industry remains deeply uncertain about how to systematize innovation.

Pricing and regulation

Pharmaceutical pricing is contentious. Governments in the United States, Europe, and everywhere else believe drug prices are too high and are trying to implement price controls or negotiate more aggressively on price. The United States is moving toward allowing Medicare to negotiate drug prices directly, which would suppress prices for new drugs. Europe has long negotiated prices with manufacturers. Even in countries with little regulatory price control, public pressure and the threat of political backlash constrains how much a company can charge.

For Novartis, this is a structural headwind. Over time, the company will be forced to accept lower prices for new drugs, which means it will need to discover more drugs or more blockbuster drugs to generate the same revenue. This is achievable in theory — new treatments for untreated diseases or for existing diseases can command premium prices for a time — but it makes the business harder.

Patent cliffs are also a regular feature: when a major drug’s patent expires, sales typically drop 50–80 percent overnight as generics flood the market. This creates a need for the company to have new drugs in the pipeline to replace the revenue. Missing a succession plan — having a blockbuster drug lose patent protection without a replacement ready to go — can devastate a pharmaceutical company’s earnings.

Understanding Novartis as an investment

Novartis trades at a valuation determined by the market’s assessment of its pipeline of future drugs and its ability to maintain pricing power. The investment case is not about innovation in the abstract but about whether the company can shepherd enough new drugs to market, whether those drugs will command strong prices, and whether competitors will dethrone them before the patent protection ends.

The quarterly earnings and the company’s annual report (Novartis is domiciled in Switzerland and files at SEC CIK 0001114448 for US listings) provide details on R&D spending, the status of drugs in various stages of development, upcoming patent expirations, and revenue trends by therapeutic area. Investors should track which drugs are approaching patent expiration, how successful the company’s recent drug approvals have been in winning market share, and whether the pipeline of future drugs includes any potential blockbusters. The cost-of-goods-sold and gross margins also matter — as drugs age and competition increases, margins shrink, and the company must improve efficiency to maintain profitability.

The key metrics to watch are: revenue growth (indicating whether new drugs are replacing those losing patent protection), the number and potential of drugs in development, the operating margin (a proxy for the company’s ability to convert sales into profit), and capital returns to shareholders. A company that is failing to generate new drugs will eventually see earnings collapse as existing drugs go off patent; a company that is successfully innovating can maintain high margins and growth for decades. Determining which Novartis is remains the core investor question.